Le Registre des lobbyistes
| Objets | Détails | Catégories |
|---|---|---|
|
Santé
|
C-64, An act respecting pharmacare - discussions around the structuring and implementation of a national pharmacare program.
|
Proposition législative, Projet de loi ou résolution, Politique ou Programme
|
|
Santé
|
Food and Drug Act - An Act respecting food, drugs, cosmetics and therapeutic devices. Discussions relating to progressive licensing and the modernization of the Food and Drug Act.
|
Proposition législative, Projet de loi ou résolution
|
|
Développement économique, Santé
|
Free trade treaty agreement as it relates to the North American Free Trade Agreement (NAFTA) and free trade negotiations as it relates to Columbia, India, and the European Union
|
Politique ou Programme
|
|
Développement économique, Relations fédérales-provinciales, Santé, Industrie
|
Intellectual Property - Changes to Patented Medicine (Notice of Compliance) (PMNOC) regulations - important regulations that can affect Eli Lilly Canada's business
|
Règlement
|
|
Santé
|
Patent Act - An Act respecting patents of invention with regard to Intellectual Property Protection for pharmaceutical products - federal court decisions that have changed the disclosure requirements regarding the utility of an invention.
|
Proposition législative, Projet de loi ou résolution
|
|
Développement économique, Relations fédérales-provinciales, Santé, Industrie
|
Patented Medicine Notice of Compliance (PMNOC) Regulations - enforcement of Intellectual Property with respect to the Canadian pharmaceutical industry.
|
Règlement
|
|
Développement économique, Relations fédérales-provinciales, Santé, Industrie
|
Patented Medicines Pricing Review Board (PMPRB) – regulations that can impact the Canadian pharmaceutical industry.
|
Règlement
|
|
Santé, Commerce international
|
Pharmaceutical and trade policy as it relates to security of supply for Canadian medicines.
|
Politique ou Programme
|
|
Développement économique, Santé
|
Pharmaceutical pricing policy arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
|
Politique ou Programme
|
|
Développement économique, Relations fédérales-provinciales, Santé, Industrie, Sciences et technologies
|
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry
|
Politique ou Programme
|
Pharmaceutical manufacturer, research and development, commercial operations.
Mathilde Merlet, President and General Manager
Adresse :
P. O. Box 73, Exchange Tower
130 King Street West, Suite 900
Toronto, ON M5X 1B1
Canada
Numéro de téléphone :
416-694-3221
Eli Lilly Canada Inc. ne possède aucune filiale qui pourrait être directement intéressée au résultat de l'engagement